Michael C. Heinrich, M.D.
- Special Interests:
- Gastrointestinal Stromal Tumors, Chronic Myeloid Leukemia
- Accepting Patients:
Dr. Heinrich provides expert care for patients with gastrointestinal stromal tumors (GIST). He is one of a handful of GIST experts on the West Coast. As part of his research program, Dr. Heinrich has authored more than 30 papers on clinical and molecular aspects of GIST and helped design and conduct the Phase II and III studies that led to FDA approval of imatinib (Gleevec) and sunitinib (Sutent) for GIST. In addition, Dr. Heinrich’s GIST clinic offers clinical studies of investigational agents for patients with advanced disease and expert molecular diagnostic consultation.
Dr. Heinrich also specializes in head and neck cancer and participates in the multidisciplinary care of these patients with members of the OHSU ENT and radiation oncology departments.
M.D., Johns Hopkins University School of Medicine, 1984
Oregon Health & Science University, 1988
Hematology/Medical Oncology, Oregon Health & Science University, 1991
American Board of Internal Medicine, (Internal Medicine), 1987 American Board of Internal Medicine (Hematology), 1990 (Recertified 2010) American Board of Internal Medicine, (Medical Oncology), 1991 (Recertified 2011)